24-fold Increase in 6-months for MEDomics Next Gen Sequence Mitochondrial Medicine DNA Diagnostic Testing

February 17, 2011

MEDomics is the DNA Diagnostic Partner for the Physician Providing Personalized Medicine

Azusa, CA (PRWEB) February 16, 2011

MEDomics provides next generation (NextGen) sequence-based DNA diagnostic testing to enable personalized medicine in the genomics era, and is transforming diagnostic testing for mitochondrial diseases. The staff at MEDomics “live and breathe” mitochondrial medicine says Steve S. Sommer, MD, PhD, Founder, President and Senior Clinical Molecular Geneticists.

After two and a half years of operations, MEDomics is experiencing rapid growth in DNA diagnostic testing revenue through acceptance of its tests for mitochondrial diseases. Clinical retail sales ($2 million dollars) exceed projections, paving the way for a strong and profitable 2011. Clinical sales increased about 11-fold in the last three months relative to the previous three months and about 24-fold in the last six months.

According to Dr. Sommer, “The mitochondrial disease tests based on Next Generation sequencing improve the utilization of blood tests to evaluate patients suspected to have mitochondrial diseases. For the physician, use of the more sensitive and comprehensive molecular tests can i) dramatically simplify testing, ii) enhance the fraction of genetic diagnoses, iii) often remove the need for painful and extensive surgical muscle sampling, iv) enable rational therapy, and v) provide prognostic information for enhanced familial risk counseling.”

MEDomics, LLC (http://www.medomics.com) is a molecular diagnostic laboratory founded in 2008, with the mission of providing Mutation Expert-based Diagnosis (“MED”) to support the physician in delivering personalized medicine based on analysis of the patient’s genome (“omics”). MEDomics was the first CLIA Certified Laboratory focused in the clinical diagnostic application of Next Generation sequencing. The mutation experts at MEDomics provide unparalleled quality interpretation to aid the practicing physician.


For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/02/prweb5077724.htm

Source: prweb

comments powered by Disqus